H1 vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 52)
H1 logo

H1

ChallengerHealthcare

Healthcare Provider Data & Intelligence

H1 is the leading healthcare provider data platform; raised $305M+ total (Series C led by Altimeter); acquired Ribbon Health (Jan 2025) and Veda Data Solutions (Jun 2025) to build end-to-end provider data infrastructure.

AI VisibilityBeta
Overall Score
C52
Category Rank
#278 of 596
AI Consensus
90%
Trend
stable
Per Platform
ChatGPT
53
Perplexity
54
Gemini
54

About

H1 is a healthcare data technology company building the industry's most comprehensive provider data platform, serving life sciences companies, health plans, hospitals, and digital health organizations. Founded in 2017 and headquartered in New York, H1 aggregates data on millions of healthcare professionals worldwide — including clinical expertise, publication records, trial participation, prescribing patterns, and network affiliations — and makes this data accessible through a unified platform and API layer. Life sciences customers use H1 to identify key opinion leaders, optimize clinical trial site selection, and target medical outreach with precision; health systems and payers use it for directory management, credentialing, and network adequacy analysis.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

52
Overall Score
93
#278
Category Rank
#1
90
AI Consensus
80
stable
Trend
up
53
ChatGPT
94
54
Perplexity
89
54
Gemini
94
54
Claude
92
57
Grok
98

Key Details

Category
Healthcare Provider Data & Intelligence
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.